2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-128418
    Benzonatate (PEGn) 32760-16-0 98%
    Benzonatate (PEGn) is a unique non-narcotic antitussive agent that has sodium channel-blocking properties and anesthetic effects on the respiratory stretch receptors.
    Benzonatate (PEGn)
  • HY-128420
    Lobeline sulfate 134-64-5 98%
    Lobeline (α-Lobeline) sulfate is a brain-penetrant nicotinic receptor agonist. Lobeline sulfate increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline sulfate is effective in smoking cessation.
    Lobeline sulfate
  • HY-128433
    CK1-IN-3 349438-74-0 99.00%
    CK1-IN-3 (compound 51) is a AC1 inhibitor with an IC50s 2.22 µM for CK-1δ.
    CK1-IN-3
  • HY-128479
    JYL-273 1391826-17-7 98%
    JYL-273 is a TRPV1 agonist, with the IC50 of 361 nM in CHO-TRPV1 cell lines.
    JYL-273
  • HY-128496
    EP2 receptor agonist 2 1807780-00-2 98%
    EP2 receptor agonist 2 (compound 18a) is a potent and selective G protein-biased EP2 receptor agonist (hEP2G protein EC50 = 13 nM, hEP2β arrestin EC50 > 10000 nM). EP2 receptor agonist 2 exhibits excellent selectivity over hEP1/3/4, hIP and hFP (EC50s > 10000 nM).
    EP2 receptor agonist 2
  • HY-128606
    Thiamine diphosphate analog 1 2606-90-8 98%
    Thiamine diphosphate analog 1 is an analog of thiamine diphosphate. Thiamine diphosphate is the active metabolite of vitamin B1 in organisms. Thiamine diphosphate targets ThDP-dependent enzymes such as transketolase and pyruvate dehydrogenase complex, acting as an essential coenzyme to exert an activating effect. Thiamine diphosphate assists in catalytic reactions in free form and initiates the catalytic cycles of various glucose-metabolizing enzymes. Thiamine diphosphate serves as a diagnostic biomarker and protective factor for Alzheimer's disease. Thiamine diphosphate can be used in research related to metabolism and Alzheimer's disease.
    Thiamine diphosphate analog 1
  • HY-128613
    Terazosin-md 2423919-77-9 98%
    Terazosin-md (compound TZ-md), a derivative of both Alfuzosin (HY-B0192) and Terazosin (HY-B0371), is an orally active α1-adrenergic receptor antagonist. Terazosin-md has the functions of improving mitochondrial metabolism, degrading various pathological protein accumulations and improving the function of vascular endothelial cells. Terazosin-md shows effect in a mouse model with Alzheimer's disease. Terazosin-md can be used for research in Alzheimer's disease and related complications, and diseases associated with protein accumulation and metabolic disorders.
    Terazosin-md
  • HY-128624
    DS39201083 2361560-81-6 98%
    DS39201083, a Conolidine derivative, is a potent and orally active analgesic agent. DS39201083 shows no agonist activity at the mu opioid receptor. DS39201083 can be used for the study of neurological diseases.
    DS39201083
  • HY-128783
    VU0090157 312622-77-8 98%
    VU0090157 is a positive allosteric modulator (PAM) of the M1 muscarinic acetylcholine receptor (mAChR). VU0090157 increases the affinity of ACh by binding to the allosteric site. VU0090157 can be used in the study of schizophrenia and Alzheimer's disease.
    VU0090157
  • HY-128794
    PF-05150122 1235406-00-4 98%
    PF-05150122 is a novel potent and selective human Nav1.7 channel blocker with the activity of inhibiting human pain signaling. PF-05150122 exhibited favorable biopharmacokinetic parameters in microdose studies, providing a basis for exploring its application in acute or chronic pain inhibition. The pharmacokinetic model of PF-05150122 predicted that at the corresponding oral dose, it could effectively reduce the 50% inhibitory concentration (IC50) of Nav1.7, demonstrating its inhibitory potential.
    PF-05150122
  • HY-12879G
    IWP-4 (GMP) 686772-17-8 98%
    IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure.
    IWP-4 (GMP)
  • HY-12883B
    PF 05089771 tosylate 1430806-04-4 98%
    PF 05089771 tosylate is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor, with IC50 values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNav1.7, cynNav1.7, dogNav1.7, ratNav1.7, and musNav1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy.
    PF 05089771 tosylate
  • HY-128891
    Eperisone 64840-90-0 98%
    Eperisone ((±)-Eperisone) is an antispasmodic agent and centrally acting muscle relaxant useful in the study of diseases characterized by muscle stiffness and pain. Eperisone acts by relaxing skeletal and vascular smooth muscle, resulting in vasodilation, decreased muscle tone, improved circulation, and inhibition of pain reflexes. Eperisone is also a potent P2X7 receptor antagonist.
    Eperisone
  • HY-129089
    (-)-MDO-NPA 81264-57-5 98%
    (-)-MDO-NPA is an N-propylnorapomorphine analog and a D1R/D2R dual-target ligand. (-)-MDO-NPA has EC50 values of 1949 nM (D1R) and 520 nM (D2R) for β-arrestin. (-)-MDO-NPA has EC50 values of 717.5 nM (D1R) and 7.7 nM (D2R) for cAMP. (-)-MDO-NPA can be used in the research of dopamine-related diseases such as Parkinson’s disease.
    (-)-MDO-NPA
  • HY-129108
    9-cis-UAB30 205252-57-9 98%
    9-cis-UAB30 is a rexinoid agonist. 9-cis-UAB30 significantly decreases the proliferation, viability, and motility of both patient-derived xenografts (PDXs). 9-cis-UAB30 induced cell-cycle arrest as demonstrated by the significant increase in the percentage of cells in G1 and a decrease in the percentage of cells in S phase by downregulating SKP2 and/or 20S proteasome activity, which leads to increased p27kip1 protein stability. 9-cis-UAB30 downregulates the abundance of stem cell marker mRNAs (Oct4, Nanog, Sox2, nestin) and upregulates the abundance of differentiation marker mRNAs (β3-tubulin, NSE, HOXC9, GAP43). 9-cis-UAB30 has no adverse effects on the central nervous system and cardiovascular system at the tested dose. 9-cis-UAB30 can be used for the study of neuroblastoma, cutaneous T-cell lymphomas, and breast cancer.
    9-cis-UAB30
  • HY-129237
    Azo-enkephalin 76995-89-6 98%
    Azo-enkephalin is an endorphin analog with significant analgesic activity. Azo-enkephalin can be used in the development of opioid analgesics.
    Azo-enkephalin
  • HY-129245
    Razobazam 78466-98-5 98%
    Razobazam (Hoe 175) is a benzodiazepine derivative with cognitive activity. Razobazam has been shown to improve learning performance in socially deprived rats. Razobazam increased avoidance scores by 18% after training. Razobazam caused significant changes in the optical density of certain areas of the rat brain, including a 22% decrease in the lateral habenula and a 25% increase in the ventral tegmental area. Razobazam also caused a 13% increase in optical density in the prefrontal cortex of rats.
    Razobazam
  • HY-129250
    AZD5213 1119807-02-1 98%
    AZD5213 is a selective and competitive human H3 receptor antagonist with a pKi value of 9.3 for hH3R. AZD5213 can be used for the research of sleep and cognitive regulation.
    AZD5213
  • HY-129278
    Lunarine 24185-51-1 98%
    Lunarine is an alkaloid, which can be isolated from the seeds of kale (Lunaria annua). Lunarine lowers the blood pressure, stimulates small intestinal motility, inhibits spontaneous contractions of uterus and nervous system, and exhibits an acute toxicity with LD50 of 62.3 mg/kg in dogs and rabbits. Lunarine exhibits antiparasitic activity through a competitive inhibition of protozoan oxidoreductase trypanothione reductase (TryR) with Ki of 304 μM.
    Lunarine
  • HY-129296
    YM-44781 free acid 173943-29-8 98%
    YM-44781 free acid is a non-peptide neuropeptide receptor antagonist with efficient NK(2) and NK(1) receptor antagonist activity. YM-44781 exhibits significant binding affinity on the NK(2) receptor (pKi = 9.94) and also on the NK(1) receptor Higher binding affinity (pKi = 9.09). In addition, YM-44781 also showed significant inhibitory effects on bladder contraction induced by selective NK(1) receptor agonists.
    YM-44781 free acid
Cat. No. Product Name / Synonyms Application Reactivity